Pielotax
Pielotax is a Khavinson short peptide bioregulator formulated for the kidney. Proposed to support renal cell gene expression and kidney functional reserve in aging models. Used in anti-aging longevity protocols targeting renal aging.
Community Rating
No ratings yet
Compound Profile
Pielotax
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Pielotax is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Proposed to support renal tubular cell gene expression in age-related renal functional decline
- May complement Epithalon in addressing organ-level aging with a specific renal target
- Kidney-targeted bioregulator for gerontological protocols addressing age-related glomerular filtration decline
- Pielotax is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Proposed to support renal tubular cell gene expression in age-related renal functional decline
- May complement Epithalon in addressing organ-level aging with a specific renal target
- Kidney-targeted bioregulator for gerontological protocols addressing age-related glomerular filtration decline
In Plain English
Simple summaryPielotax is a synthetic tetrapeptide from the Khavinson bioregulator series targeted at kidney and renal pelvis tissue. The Khavinson group developed it from renal tissue peptide analysis and proposes it restores tubular epithelial cell gene expression, supports renal detoxification capacity, and improves kidney function in age-related nephrosclerosis. It has been studied in small Russian clinical trials in patients with chronic kidney disease, diabetic nephropathy, and age-related renal decline. The oral enteric-coated Cytomaxes formulation is the standard delivery.
- Proposed to support renal tubular cell gene expression in age-related renal functional decline
- May complement Epithalon in addressing organ-level aging with a specific renal target
- Kidney-targeted bioregulator for gerontological protocols addressing age-related glomerular filtration decline
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Pielotax?
Tap any underlined term for an instant definition.
Pielotax is a peptide bioregulator from Professor Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, derived from kidney tissue. It is formulated to target renal aging — the progressive decline in glomerular filtration rate, tubular function, and renal reserve that accompanies human aging.
Age-related changes in the kidney (nephrosclerosis) include: glomerulosclerosis, tubulointerstitial fibrosis, reduced GFR (~1 mL/min/year after age 40), impaired tubular secretion, and diminished ability to respond to acid-base and volume challenges. These changes are accelerated by hypertension, diabetes, and chronic inflammation.
In the Khavinson bioregulator framework, Pielotax contains short regulatory peptides derived from kidney cortex tissue, proposed to interact with DNA and chromatin in renal cells to help maintain or restore youthful gene expression patterns. This would potentially support tubular cell maintenance, reduce fibrotic signaling, and preserve renal functional capacity in aging.
Like other Khavinson bioregulators, Pielotax is used as part of comprehensive multi-organ anti-aging protocols, often combined with cardiovascular bioregulators (Vesugen, Cardiogen), epithelial bioregulators (Chonluten, Bronchogen), and the flagship anti-aging peptides (Epithalon, Thymalin). The combination approach reflects the Khavinson group's view that systemic aging requires coordinated multi-organ bioregulatory intervention.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Pielotax. See all Healing & Recovery peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Oral capsule or SC injection. Part of comprehensive organ-targeted anti-aging protocols.
What the research doesn't show
Pielotax has the same limitations as all Khavinson bioregulators. For kidney disease research with clinical relevance, the ACE inhibitor/ARB literature, SGLT-2 inhibitor data for diabetic nephropathy, and ARA-290 clinical programs represent the state of evidence. Pielotax is documented here as part of the complete Khavinson catalog.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Pielotax, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Pielotax has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: proposed to support renal tubular cell gene expression in age-related renal functional decline.
The most commonly reported side effect in research subjects is minimal adverse effects reported in the khavinson program context. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
ARA-290 (cibinetide) has Phase 2 human data in diabetic complications including neuropathy -- a more advanced clinical program for peptide approaches to diabetic complications. Angiotensin 1-7 has documented renal protective effects in preclinical models. ACE inhibitors and ARBs are the established standard of care for diabetic nephropathy protection with outcomes data. Pielotax's evidence base is incomparably weaker.
Compare Pielotax side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.